A Phase I, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of VX-840 in Healthy Subjects
Latest Information Update: 14 Dec 2022
At a glance
- Drugs VX-840 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 06 Dec 2022 Status changed from recruiting to completed.
- 29 Apr 2022 Status changed from not yet recruiting to recruiting.
- 19 Apr 2022 New trial record